PhRMA Spies Opportunities Amid ‘Remarkable’ Japan Improvements
This article was originally published in The Pink Sheet Daily
Executive Summary
PhRMA cites improvements in NDA submission delays and drug review times by Japan’s PMDA but will continue to work with the regulator to address issues such as multiregional clinical trial guidelines for Phase I data, enhancing priority reviews and introducing rolling submissions.